Evidence map›Paper›PMID 40548152›Full record

ArticleCureus2025

Cancer of Unknown Primary: A Case Report on the Recognition of Its Clinical Entity and Standard of Care Management.

Alexander Lazzaro, Maya Srinivasan, Hussein Assi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexander LazzaroMedicine, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, USA.
Maya SrinivasanHematology and Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, USA.
Hussein AssiHematology and Oncology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer of unknown primary (CUP) is a distinct and well-established clinical entity that encompasses a heterogeneous group of histologically proven cancers that present unique diagnostic and therapeutic challenges. This case describes a male patient in his late 60s who presented with nonspecific gastrointestinal complaints. A comprehensive workup, including clinical evaluation and various biochemical, imaging, and invasive histopathologic tests, led to the diagnosis of CUP following consultation with medical oncology specialists. A decision was made to forgo further invasive molecular tissue sampling in search of a primary malignant process in favor of initiating systemic chemotherapy. The patient possessed an unfavorable set of prognostic signs. Rapid clinical deterioration occurred the day after treatment initiation. A goals of care conversation led to a transition towards comfort measures only care, and the patient ultimately passed away. This case highlights the importance of non-oncologically trained providers recognizing CUP as its own entity to facilitate standard of care management. Future research is needed to establish benefits in clinical trials looking at molecular tumor profiling and site-specific therapies for this rare malignancy.

Indexed as

cancer of unknown origincytokeratinsdiagnostic mysteryimmunohistochemistry (ihc)metastatic adenocarcinoma of unknown primary

Identifiers

PMID40548152
PMCPMC12180934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.